ZLAB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

17.405

Open

17.190

VWAP

17.00

Vol

600.00K

Mkt Cap

2.00B

Low

16.995

Amount

10.00M

EV/EBITDA(TTM)

--

Total Shares

111.00M

EV

1.00B

EV/OCF(TTM)

--

P/S(TTM)

4.00

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

Show More

Events Timeline

(ET)

2026-01-06

07:40:00

Zai Lab Receives Approval for Augtryo to Treat Adult Solid Tumors

2025-12-24 (ET)

2025-12-24

10:10:00

Zai Lab Shares Rise 7.4% to $18.77

2025-12-23 (ET)

2025-12-23

09:10:00

U.S. Economic Growth Exceeds Expectations, Stock Futures Edge Lower

2025-12-23

07:50:00

Zai Lab Receives China's Approval for Cobenfy to Treat Schizophrenia in Adults

2025-12-08 (ET)

2025-12-08

07:20:00

Zai Lab Initiates Global Clinical Trial for ZL-1503

2025-12-07 (ET)

2025-12-07

12:40:00

Zai Lab's Drugs Renewed in 2025 National Reimbursement Drug List

2025-11-06 (ET)

2025-11-06

08:22:55

Zai Lab projects FY25 revenue to reach a minimum of $460M, while consensus estimates stand at $556.41M.

2025-11-06

08:21:11

Zai Lab Announces Q3 Earnings Per Share of 3 Cents, Below Consensus Estimate of 29 Cents

News

an image of seekingalpha

01-14seekingalpha

Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score

an image of seekingalpha

01-12seekingalpha

Seeking Alpha Releases Q4 Stock Ratings, Micron and Others Rated Strong Buy

an image of Newsfilter

01-06Newsfilter

Zai Lab Receives NMPA Approval for AUGTYRO™ in NTRK-Positive Solid Tumors

an image of Businesswire

01-06Businesswire

Zai Lab Receives NMPA Approval for AUGTYRO in NTRK-Positive Solid Tumors

an image of Businesswire

01-05Businesswire

Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

an image of NASDAQ.COM

01-05NASDAQ.COM

GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update

5 Analyst Rating

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is 47.93 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.70

Averages

47.93

High

74.00

Current: 0.000

Low

25.70

Averages

47.93

High

74.00

UBS

Buy

initiated

$35

AI Analysis

2026-01-07

Reason

UBS

Price Target

$35

AI Analysis

2026-01-07

initiated

Buy

Reason

UBS initiated coverage of Zai Lab (ZLAB) with a Buy rating and $35 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Goldman Sachs

downgrade

2025-11-03

Reason

Goldman Sachs

Price Target

2025-11-03

downgrade

Reason

Goldman Sachs analysts removed Zai Lab from the firm's APAC Conviction List as part of its monthly update.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZLAB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is -18.08, compared to its 5-year average forward P/E of -18.17. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-18.17

Current PE

-18.08

Overvalued PE

2.56

Undervalued PE

-38.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-14.44

Current EV/EBITDA

-27.61

Overvalued EV/EBITDA

-0.33

Undervalued EV/EBITDA

-28.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

18.88

Current PS

3.52

Overvalued PS

42.45

Undervalued PS

-4.69

Financials

AI Analysis

Annual

Quarterly

Whales Holding ZLAB

Frazier Life Sciences Management, LP

Rock Springs Capital Management LP

RTW Investments, LP

Qiming Weichuang Venture Capital Management (Shanghai) Company Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 17.25 USD — it has increased 0.29 % in the last trading day.

What is Zai Lab Ltd (ZLAB)'s business?

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

What is the price predicton of ZLAB Stock?

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is47.93 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

Zai Lab Ltd revenue for the last quarter amounts to 116.00M USD, increased 13.52 % YoY.

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

Zai Lab Ltd. EPS for the last quarter amounts to -0.03 USD, decreased -25.00 % YoY.

How many employees does Zai Lab Ltd (ZLAB). have?

Zai Lab Ltd (ZLAB) has 1869 emplpoyees as of January 30 2026.

What is Zai Lab Ltd (ZLAB) market cap?

Today ZLAB has the market capitalization of 2.00B USD.